Management said fiscal 2026 revenue was USD 622 million, up 5% as reported and 2% organically, exceeding the high end of its guidance range on stronger Multiomics activity in the fourth quarter. It said fiscal 2026 performance was below its expectations, reflecting customerCapitalconstraints and …
For the nine months, net loss was USD 132.74 million, or USD 1.66 per share, against USD 95.25 million, or USD 6.49 per share. Weighted average shares outstanding were about 80.2 million for the quarter against 43.5 million a year earlier, which affects per …
Total operating expenses were USD 12.1 million, up from USD 11.0 million.Research and Developmentspending was USD 7.0 million, down from USD 7.4 million, while general and administrative costs rose to USD 5.1 million from USD 3.5 million. Interest and other income contributed USD 2.1 …
Management called it the strongest operating quarter of 2026 and cited meaningful year-over-year growth in same-location revenue, NOI and adjusted EBITDA. Same-location revenue grew 12.8% and same-location NOI rose 18.4% to USD 6.3 million from USD 5.3 million, the third consecutive quarter of acceleration …
The GAAP net loss was USD 32.5 million, or USD 0.40 per diluted share, against a net loss of USD 19.1 million, or USD 0.24 per share. Management said the loss reflected a USD 40.7 million pre-tax non-cash impairment charge on the B&M and …
Net loss was USD 8,479 thousand against USD 9,961 thousand. The loss per common share, basic and diluted, was USD 0.81 against USD 0.94. The filing also reports interest income from notes receivable of USD 386 thousand, with none a year earlier.
Research and development expense was USD 8.5 million against USD 14.4 million, and general and administrative expense was USD 4.4 million against USD 4.2 million. Operating expenses totaled USD 13.0 million against USD 20.8 million.
The source table carried quarterly style estimates of USD 0.02 per share and USD 59.85 million in revenue but no actuals. Because the filing covers a full fiscal year, no beat or miss is stated against those estimates.
Management said consumables revenue was USD 4.7 million, up 24% on sales to existing customers in the Americas. Software revenue was USD 1.1 million, down 31% on a lower number of VIA software licenses sold. Other revenue, which includes instruments and services, was USD …
Revenue fell 8.9% sequentially and 24.5% year over year, which management called its cleanest comparison of the newBusinessmodel now that the MLM impact is largely behind it. Nine-month net income was USD 7.0 million against a net loss of USD 8.1 million a year …